Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-CAR-T Cell Therapy for Refractory B Cell Lymphomas
NCT04429438Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR19, 4SCAR20 + 4SCAR22 + 4SCAR70 + 4SCAR-PSMA + 4SCAR13 + 4SCAR79b + 4SCAR-GD2 in B cell lymphoma, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR194SCAR20 + 4SCAR22 + 4SCAR70 + 4SCAR-PSMA + 4SCAR13 + 4SCAR79b + 4SCAR-GD2
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04429438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429438.